Thin Spot Inc

Thin Spot Inc operates as a medical weight loss clinic in Albuquerque, New Mexico, under the clinical direction of Mark J. Holland, MD. The practice focuses on pharmacologically supported weight management programs designed for patients who have not achieved sustainable results through diet and exercise alone. Dr. Holland's approach integrates GLP-1 receptor agonist therapy with metabolic assessment and ongoing medical supervision, providing structured weight loss interventions for adults with obesity or weight-related metabolic conditions.

The clinic's treatment protocols center on two FDA-approved GLP-1 agonist peptides: liraglutide and semaglutide. Liraglutide, administered as a daily subcutaneous injection, works by mimicking the incretin hormone GLP-1 to regulate appetite and slow gastric emptying. Semaglutide, available as a weekly injection, offers a longer duration of action with similar mechanisms that reduce hunger signals and improve glycemic control. Both peptides have demonstrated efficacy in clinical trials for weight reduction when combined with lifestyle modification. Thin Spot Inc tailors peptide selection and dosing to individual patient profiles, considering factors such as baseline body mass index, comorbid conditions including type 2 diabetes, and tolerance to gastrointestinal side effects that commonly occur during titration phases.

Dr. Holland brings physician-level oversight to each patient's weight loss program, conducting initial medical evaluations that include metabolic panel review, cardiovascular risk assessment, and screening for contraindications to GLP-1 therapy. His clinical model emphasizes hormone optimization as a complementary component to peptide therapy, recognizing that thyroid dysfunction, sex hormone imbalances, and cortisol dysregulation can impede weight loss progress. Patients receive baseline hormone testing when clinically indicated, with treatment adjustments made to address deficiencies that may contribute to metabolic resistance. This integrated approach distinguishes the practice from weight loss programs that rely solely on caloric restriction or single-agent pharmacotherapy.

Patients at Thin Spot Inc attend in-person consultations at the Albuquerque clinic, where they receive instruction on proper injection technique, medication storage, and management of common adverse effects such as nausea and constipation. Follow-up visits occur at regular intervals to monitor weight trends, assess medication tolerance, and adjust dosing according to response. The clinic provides ongoing access to medical staff for questions about medication administration or side effect management between scheduled appointments. Dr. Holland's protocols include periodic laboratory monitoring to track metabolic markers and ensure patient safety throughout the treatment course, with particular attention to pancreatic enzyme levels and renal function in patients receiving long-term GLP-1 therapy.

Thin Spot Inc serves patients throughout the Albuquerque metropolitan area who require physician-supervised weight management with advanced pharmacologic support. The clinic's focus on GLP-1 peptides reflects current evidence supporting these agents as among the most effective medical interventions for obesity, with clinical trial data showing average weight reductions of 15-20% of body weight when combined with lifestyle modification. By limiting the practice scope to medical weight loss and hormone optimization, Dr. Holland maintains specialized expertise in metabolic medicine rather than offering a broad menu of aesthetic or wellness services. This focused model allows for deeper clinical knowledge of peptide pharmacology, drug interactions, and the management of complex cases involving multiple metabolic comorbidities.